Erenumab efficacy reported for Australian migraine patients

Early Australian experience with the CGRP inhibitor erenumab (Aimovig) shows it is an effective and well-tolerated migraine preventative therapy in real world usage. A review of the non-PBS-listed drug’s use in three Australian migraine centres via a product familiarisation program or a $800/month paid access scheme found that it provided consistent responses at three and ...

Already a member?

Login to keep reading.

© 2021 the limbic